Patents by Inventor Peter M. Munson

Peter M. Munson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
    Publication number: 20090325936
    Abstract: The present invention relates to compounds represented by Formula (I) and Formula (II): (I) (II) or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.
    Type: Application
    Filed: December 14, 2007
    Publication date: December 31, 2009
    Inventors: Mark T. Bilodeau, Christopher S. Burgey, Zhengwu James Deng, Nathan R. Kett, Jeffrey Melamed, Peter M. Munson, Kausik K. Nanda, Wayne Thompson, B. Wesley Trotter, Zhicai Wu, John C. Hartnett
  • N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
    Patent number: 7259157
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: August 21, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, John W. Butcher, Charles McIntyre, Christopher F. Claiborne, David A. Claremon, John A. McCauley, Joseph J. Romano, Wayne Thompson, Peter M. Munson
  • N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
    Patent number: 7217716
    Abstract: Compounds represented by Formula (I): (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: May 15, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, David A. Claremon, Brian E. Libby, John W. Butcher, John A. McCauley, Nigel J. Liverton, Peter M. Munson, Kevin T. Nguyen, Brian Phillips, Wayne Thompson
  • N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
    Patent number: 7053089
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: May 30, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, John W. Butcher, David A. Claremon, Brian E. Libby, Nigel J. Liverton, Peter M. Munson, Kevin T. Nguyen, Brian Phillips, Wayne Thompson, John A. McCauley
  • N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
    Publication number: 20040209889
    Abstract: Compounds represented by Formula (I): (I)or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Application
    Filed: July 29, 2003
    Publication date: October 21, 2004
    Inventors: Christopher F Claiborne, David A Claremon, Brian E Libby, John W Butcher, John A McCauley, Nigel J Liverton, Peter M Munson, Kevin T Nguyen, Brian Phillips, Wayne Thompson
  • N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
    Publication number: 20030119811
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: April 2, 2002
    Publication date: June 26, 2003
    Inventors: Nigel J. Liverton, John W. Butcher, Charles McIntyre, Christopher F. Claiborne, David A. Claremon, John A. McCauley, Joseph J. Romano, Wayne Thompson, Peter M. Munson
  • 1,4 substituted piperidinyl NMDA/NR2B antagonists
    Publication number: 20030018038
    Abstract: Novel piperidinyl compounds substituted in the 1- and 4-positions are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Application
    Filed: August 9, 2002
    Publication date: January 23, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson, Janusz Kulagowski, Willie Whitter, Ian Huscroft
  • 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
    Patent number: 6495561
    Abstract: 4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C6alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: December 17, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Wayne J. Thompson, David A. Claremon, Peter M. Munson, John A. McCauley
  • 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
    Patent number: 6489477
    Abstract: Novel 2-aza-bicyclo[2.2.2]octanes substituted in the 2-position are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: December 3, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson
  • N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
    Publication number: 20020165241
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: February 20, 2002
    Publication date: November 7, 2002
    Inventors: Christopher F. Claiborne, John W. Butcher, David A. Claremon, Brian E. Libby, Nigel J. Liverton, Peter M. Munson, Kevin T. Nguyen, Brian Phillips, Wayne Thompson, John A. McCauley
  • 1,4 substituted piperidinyl NMDA/NR2B antagonists
    Patent number: 6476041
    Abstract: Novel piperidinyl compounds substituted in the 1- and 4-positions are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: November 5, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson, Janusz Kulagowski, Willie Whitter, Ian Huscroft
  • 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
    Patent number: 6432976
    Abstract: Novel 3-substituted 8-aza-bicyclo[3.2.1]octanes (commonly known as “tropanes”) substituted in the 8-position are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson, Brian Phillips
  • 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
    Publication number: 20020055519
    Abstract: 4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C6alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Application
    Filed: May 21, 2001
    Publication date: May 9, 2002
    Inventors: Wayne I. Thompson, David A. Claremon, Peter M. Munson, John A. McCauley
  • 2-cyclohexyl quinazoline NMDA/NR2B antagonists
    Patent number: 6380205
    Abstract: 4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C6alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson, John A. McCauley
  • 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
    Patent number: 6369076
    Abstract: Novel 5-benzyl-octahydroindoles and 6-benzyl-decahydroquinolines substituted in the 1-position are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: April 9, 2002
    Assignee: Merck & Co. Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson
  • 2-Cyclohexyl quinazoline NMDA/NR2B antagonists
    Publication number: 20020032207
    Abstract: 4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C6alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Application
    Filed: May 21, 2001
    Publication date: March 14, 2002
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson, John A. McCauley
  • 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
    Patent number: 6291499
    Abstract: Novel 4-substituted cyclohexanes substituted in the 1-position with 2-benzimidazoles, 2-imidazopyridines, or 4-imidazoles either directly or through a C1-C4alkyl, cycloalkyl, hydroxyalkyl, alkoxy or aminoalkyl chain are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: September 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson, John A. McCauley
  • Benzodiazepine hydrazide derivatives as inhibitors of HIV integrase
    Patent number: 5939414
    Abstract: Compounds having a benzodiazepine hydrazide core are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: August 17, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Ian M. Bell, Daria Jean Hazuda, James P. Guare, Jr., Peter M. Munson, Wayne J. Thompson, Joseph P. Vacca
  • Muscarine agonists
    Patent number: 5718912
    Abstract: This invention is concerned with novel 1-?cycloalkylpioeridin-4-yl!-2H benzimidazolones, their compositions and method of use. The novel compounds are selective muscarinic agonists of the m2 subtype with low activity at the m3 subtype. The compounds are effective for the treatment of glaucoma with fewer side effects than the pilocarpine therapy.
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Wayne J. Thomspon, Pierre Mallorga, Richard W. Ransom, Ian M. Bell, Michael F. Sugrue, Peter M. Munson